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A B S T R A C T
Bone morphogenetic proteins (BMP) have the ability to induce ectopic bone formation1–10. The findings of their expres-
sion in prostate cancers have been linked with specifically tumor progression to bone and development of osteosclerotic
metastases7–15. We investigated the expression pattern of BMP-2/4, -6 and -7 and the receptors BMPR-IA,-IB and -II in
normal human prostate, organ-localized and metastatic prostate cancers. The expression we also examined in skeletal
metastases caused by prostate cancer. In localized prostate cancers we found increased expression of BMP-6 and de-
creased expression of BMP-2/4 and -7. In metastatic prostate cancers the expression of examined BMPs decreased. The
expression of BMPRs showed the tendency to be lower with progression of prostate cancer but the expression of BMPR-II
was completely absent in metastatic prostate cancers. In bone metastases caused by prostate cancer we found high expres-
sion of BMP-2/4, -6 and -7. Decreased expression of BMPs and lose of BMPR-II expression, could suggest that the influ-
ence of BMPs on prostate cancer cells is inhibited and plays an important role in prostate cancer pathogenesis. High ex-
pression of osteogenic BMPs in prostate cancer bone metastases could explain their osteosclerotic properties.
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Introduction
Prostate cancer is the most common cause of cancer
death in male population in Western countries1–3. Ad-
vanced prostate cancer is commonly associated with the
development of skeletal metastases. More than 90% of
skeletal metastases caused by prostate cancer are osteo-
blastic bone lesions3–9. In contrary, skeletal metastases
from other malignances are most frequently osteolytic
bone lesions10. The linkage between prostate cancer and
bone as well as predominantly presence of osteoblastic
activity in the metastatic bone lesions remains still poor-
ly understood11–13.
Human prostate cells produce bone morphogenetic
proteins (BMPs), the members of the transforming
growth factor beta (TGF-ß) superfamily. BMPs were orig-
inally identified as factors that were able to induce ecto-
pic bone and cartilage formation in vivo and were in-
volved as multifunctional regulator factors in cellular
differentiation, cellular proliferation, apoptosis and orga-
nogenesis14–18. The expression of BMPs in malignant
prostate cells and prostate cancer cell lines brings a new
insight on relationship between prostate cancer and bone
microenvironment. Several BMPs were detected in hu-
man normal and malignant prostate cells. Mostly the ex-
pression of BMP-2,-3,-4,-5 and -6 was examined19–23. Ma-
suda et al investigated the expression of BMP-7, one of
the members of BMPs family with strong osteoinductive
capacity24. BMP-6 expression has been predominantly
found in human prostate cancers with established skele-
tal metastases comparing with non-metastatic prostate
cancer20,21. Several studies have shown a correlation be-
tween elevated BMP-6 expression and cancer severity
and it was suggested that the effect of the BMP-6 in the
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surrounding bone environment may be related to the
osteoblastic nature of the metastatic lesions24–26. Addi-
tionally, bone metastases could be osteoblastic or osteo-
lytic bone lesions and thinking about the expression of
BMPs it is indicated to differentiate the type of bone ac-
tivity. In vitro studies have shown that BMP -2, -4, -6 and
-7 have no direct effect on prostate cancer cell growth,
but BMP -2, -4 and -6 increase the in vitro invasive abil-
ity of prostate cancer cells27,28. Feeley et al have found
that BMP-7 inhibits PC-3 cell proliferation and BMP-6
inhibits the proliferation of human renal cell cancer
(RCC) cell line28. BMP-6 and BMP-7 expression has been
even detected in metastatic bone lesions caused by pros-
tate cancer24,29.
BMPs act over binding to membrane receptors known
as BMP receptors (BMPRs). BMPRs are heteromeric
complex that consists of two types I receptors named
type -IA and –IB and one type –II receptor. It has been
shown that all members of BMPs bind to BMPR-II in
combination with BMPR-IA or BMPR-IB. BMP binding
results in crossphosphorylation of one of type I receptors
by BMPR-II30. The effect of BMP-2, -4 and -7 is mediated
by binding on BMPR-IB31. Followed by the expression of
all three BMPRs in normal prostate cancer cells, de-
creased expression of BMP receptors type -IA, -IB and -II
has been found in prostate cancer cells27,30,31,33. It has
been assumed that defective BMP signaling may lead to
an enhanced tumorigenic potential of prostate cancer
cells and consequently contribute to tumor progres-
sion30,31. RCC cell lines with the lack of BMPR-II were re-
sistant to the growth-inhibitory effect of BMP-631.
The aim of the present study was, using immuno-
histochemistry on same tissue samples, to examine the
expression of BMP-2/4, -6 and -7, and BMPR-IA, -IB and
-II in human normal prostate tissue, organ-localized
prostate cancer and metastatic prostate cancer with es-
tablished osteosclerotic bone metastases and to clarify
the potential role of BMPs in prostate cancer pathoge-
nesis. The expression of BMP-2/4, -6 and -7 and BMPRs
in non-matched samples of bone metastases caused by
prostate cancer was examined, too.
Materials and Methods
We analyzed tissue samples of prostate cancer ob-
tained from the patients treated at the Department of
Urology, University Hospital of Rijeka, Croatia in the pe-
riod from 2002 to 2007. All the patients involved in this
study were informed about the aims of the study and
signed informed consent letter. The patients with diag-
nosed prostate cancer were divided in two groups. The
first was a group of the patients with primary prostate
cancer without any clinical signs of tumor progression
and without bone metastases. For that group we selected
twenty one patients and they all underwent to radical
prostatectomy. The second group consisted of the pa-
tients with metastatic prostate cancer, with proved bone
metastases. In that group we selected twenty one pa-
tients, too. The patients with metastatic prostate cancer
who already received hormonal therapy were not in-
cluded into the study. The age of patients ranged from 55
to 81 years (mean±SD, 69.5±6.2). From the archival tis-
sue samples stored at the Department of Pathology, Fac-
ulty of Medicine, University of Rijeka, following the ap-
proval of the local ethic committee, we obtained 21
specimens of nonmetastatic prostate cancer and 21 speci-
men of metastatic prostate cancer tissue. Tissue samples
of nonmetastatic prostate cancer were taken after trans-
rectal prostate needle biopsy and patohistological finding
were confirmed after radical prostatectomy. Tissue sam-
ples of metastatic prostate cancer were also taken after
transrectal prostate needle biopsy. Normal prostate tis-
sue was obtained from aged matched individuals (10
specimens). Tissue samples were pathohistologically an-
alyzed. Prostate tissue that was pathohistologically con-
firmed as prostate cancer, was graded using Gleason
scoring system according to the World Health Organiza-
tion (WHO) classification criteria35. For determining the
stage of prostate cancer regarding to its affinity to metas-
tasis to the bone and produce bone lesions, isotope bone
scanning of the whole body, and radiography of the verte-
bral column with pelvis and thoracic region were done.
After detection of bone metastases by both plain radiog-
raphy and bone scyntigraphy, the characteristics of bone
metastasis were determined. All bone metastases were
distinguished as predominantly osteosclerotic bone le-
sions. Other clinical data we obtained from patient’s
medical records.
From patient’s charts we obtained data about serum
prostate specific antigen (PSA) values and serum alka-
line phosphatase (AP) values. Serum PSA was measured
using IMx assay (Abbott Laboratories, Abbot Park, IL,
USA) and the reference for this assay ranged from 0 to
4.0 ng/mL. Serum total alkaline phosphates (AP) activity
was determined using a kinetic color test on Olympus an-
alyzer using p-nitrophenylphosphate substrate at pH
10.4, normal range for adults 30–120 U/L.
The next group consisted of the patients who suffered
pathological bone fracture but afterwards was deter-
mined that the cause of bone fracture was prostate can-
cer metastatic lesion. After bone surgery procedures the
bone tissue samples were sent for patohistological exami-
nation. For five patients bone lesions were detected as
bone metastases of prostate cancer. So we included these
five patients in the research. Patohistologically those
bone metastatic lesions were described as osteoblastic.
Tissue samples preparation
Prostate tissue specimens were fixed in 10% buffered
formalin and embedded in paraffin wax. Serial sections
at 3 µm thickness were made, mounted on glass slides
and kept at room temperature until use. The first of se-
quential sections from each specimen was stained with
hematoxylin and eosin (H&E). Tissue samples of bone
metastases passed prior sectioning additional procedures
of tissue preparations. Bone tissue samples were fixed in
solution composed of concentrated formaldehyde (50%),
methanol (46%) and PBS (4%). Following this fixation,
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the tissue was transferred in 70% ethanol and decalcified
in Osteodec (Bioptica, Milano, Italy).
Immunohistochemistry
Tissue slices were mounted on glass slides coated with
3-aminopropyltriethoxy silane (APES, Sigma, St. Louis,
MO, USA), air-dried, and stored at 4 °C until processing
for indirect immunoperoxidase staining. Briefly, tissue
slices were deparaffinized in xylene and rehydrated in
ethanol. Endogenous peroxidase and nonspecific binding
were blocked by incubation in 0.3% H202 in methanol and
10% non-immune serum. The sections were incubated
with primary antibody for 60 minutes at room tempera-
ture. Anti-BMP-2/4, -6, -7, anti-BMPR-IA, -IB and -II
were goat polyclonal antibodies purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). After the in-
cubation with a primary antibody, secondary biotynilated
antibody was applied according to the manufacturer’s
protocol (DAKO, LSAB@+ Kit Peroxidase, Carpentaria,
CA, USA). Peroxidase conjugated streptavidin was added
and the site of antigen binding was visualized using AEC
+ Substrate Chromogen (DakoCytomation). Sections
were counterstained with hematoxylin. Slides used as
negative control were processed either with PBS buffer
or the secondary antibody alone.
Assessment of Immunohistochemistry
Assessment of immunohistochemistry was performed
by three independent observers (M.K., D.M. and J.S.)
that were blinded to patient outcome. Cytoplasmic ex-
pression was assessed as absent or present. The cells
with positive reaction were counted and scored as a per-
centage of the total number of malignant cells present in
15 high powerfield (400x magnifications). Cell counting
was done by using an image analyzer system equipped
with a software package (Issa, VAMS, Zagreb, Croatia).
Before starting the assessment the tissue sample was
looked through by pathologists and was signed the area
of clear prostate cancer. In the signed area 15 neighbor-
ing powerfields were analyzed. Conventional sections of
normal prostate were scored using the same method with
assessment of 15 randomly selected powerfields of each
section. Staining score of counted cells revealed a signifi-
cant interobserver concordance. The sample with more
then 10% of positively stained cells was declared as posi-
tive sample.
Statistical Analysis
The data was elaborated and analyzed using Sta-
tistica 6.1 software package (StatSoft lnc., Tulsa, OK,
USA). The observations were described by their means±
standard deviations, or with medians with 10th to 90th
percentile range, where suitable. Normality check was
performed with Shapiro-Wilks test. Following, the groups
were compared using non parametric tests: Kruskal-
-Wallis ANOVA for comparison of multiple groups or
Mann-Whitney U test for comparison of two groups. A
value of p<0.05 was required for significance. Because of
the small number of metastatic bone samples involved,
only descriptive analyses could be performed.
Results
By immunohistochemistry we investigated the ex-
pression of BMP-2/4, -6 and -7, and BMPR IA,-IB and II
in epithelial glandular tissue of normal human prostate
and in prostate cancer cells of organ-localized prostate
cancer and metastatic prostate cancer with proved bone
metastases. Furthermore we analyzed metastatic bone
lesions from prostate cancer. Acquired data were statisti-
cally analyzed and in the most cases the distribution of
data was not normal but the distributions had similar
shapes.
The expression of BMP-2/4,-6 and -7 was found in epi-
thelial glandular cells from all samples of normal pros-
tate and the percentage of positive cells was different for
each BMP (Figure 1a,d,g). According to the percentage of
positive cells the predominant expression of BMP-2/4 and
BMP-7 was found in normal prostate tissue (Table 1).
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TABLE 1
EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) IN NORMAL PROSTATE (NP) AND PROSTATE CANCER (PC) (MEAN±SD)
BMPs NP Localized PC Metastatic PC
% positive cells no. of cases % positive cells no. of cases % positive cells no. of cases
BMP-2/4 87.77±11.4 10/10 71.71±24.40 21/21 62.88±16.03 20/21 (95%)
BMP-6 64.51±12.95 10/10 88.63±13.27* 21/21 40.98±15.74** 6/21 (29%)**
BMP-7 94.63±0.89 10/10 80.37±22.10 21/21 46.23±11.58** 7/21 (33%)**
* p<0.05 localized PC vs. NP, ** p<0.05 metastatic PC vs. localized PC
TABLE 2
VALUES OF GLEASON SCORE, SERUM CONCENTRATION OF
PROSTATE SPECIFIC ANTIGEN (PSA) AND SERUM TOTAL
ALKALINE PHOSPHATASE IN PATIENTS WITH LOCALIZED
AND METASTATIC PROSTATE CANCER (PC) (MEAN±SD)
Localized PC Metastatic PC
Gleason score 4±1 6±21
PSA 10.5±2.8 ng/mL 105.1±147.1 ng/mL*
Alkaline
phosphatase 63.5±24.3 U/L 526.9±342.6
b U/L*
* p<0.05, metastatic PC vs. localized PC
The patients with organ-localized prostate cancer had
significantly lower Gleason score, lower PSA serum con-
centration and lower serum alkaline phosphatase com-
pared to the patients with metastatic prostate cancer and
proven bone metastases. (Table 2).
BMP-2/4 was strongly expressed in organ-localized
prostate cancer while in metastatic prostate cancer the
expression decreased. In all tissue samples of organ-lo-
calized tumor and metastatic prostate tumor we found
positive expression (Figure 1b,c, Table 1).
BMP-7 expression slightly decreased in organ-local-
ized prostate cancers compared to the normal prostate.
In metastatic prostate cancers the percentage of BMP-7
positive cells even more significantly decreased (P<0.001)
(Figure 1h,i). The expression was found in almost all tis-
sue samples of organ-localized prostate cancer while in
metastatic prostate cancers the expression was found
only in 7 out of 21 samples what additionally indicated
BMP-7 expression significant reduction (Table 1).
The percentage of BMP-6 positive cells was higher in
organ-localized prostate cancer tissue than in normal
prostate tissue but the difference was not statistically
significant. In metastatic prostate cancer tissue the ex-
pression of BMP-6 was significantly lower in comparison
to the localized prostate cancer (P<0,01) (Figure 1e,f).
Even more, we found only 6 out of 21 tissue samples of
metastatic prostate cancer with positive expression (Ta-
ble 1).
BMPR-IA, BMPR-IB and BMPR-II were expressed by
the cells of normal prostate (Table 3). The expression
was localized in the epithelial glandular cells and in some
cases in stromal cells (Figure 2a,d,g).
The expression of BMPR-IA, BMPR-IB and BMPR-II
in organ-localized prostate cancer was not distinct to the
expression in normal prostate (Table 3). However, in
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Fig. 1. The expression of bone morphogenetic protein (BMP) -2/4
in normal prostate (a), in localized prostate cancer (b), in meta-
static prostate cancer (c); the expression of BMP-6 in normal
prostate (d), in localized prostate cancer (e), in metastatic pros-
tate cancer (f); the expression of BMP-7 in normal prostate (g), in
localized prostate cancer (h), in metastatic prostate cancer (i).
Fig. 2. The expression of bone morphogenetic protein receptor
(BMPR) -IA in normal prostate (a), in localized prostate cancer
(b), in metastatic prostate cancer (c); the expression of BMPR-IB
in normal prostate (d), in localized prostate cancer (e), in meta-
static prostate cancer (f); the expression of BMPR-II in normal
prostate (g); in localized prostate cancer (h); in metastatic pros-
tate cancer (i);. the expression of bone morphogenetic protein
(BMP) -2/4 in metastatic bone lesion (j); the expression of BMP-6
in metastatic bone lesion (k); the expression of BMP-7 in meta-
static bone lesions (l).
metastatic prostate cancer cells we found significantly
decreased expression of receptors type IA and IB, and
loss of expression for BMPR-II (Figure 2b,e,h). The lower
expression for BMPR-IA and -IB was also manifested by
significantly reduced number of positive samples of met-
astatic prostate cancer. (Table 3, Figure 1c,f,i).
BMP-2/4, -6 and -7 were strongly expressed by meta-
static prostate cancer cells in skeletal metastases (Table
4, Figure 2j,k,l).
Analysis of prostate cancer bone metastases showed
also a decreased expression of BMPRs. The expression of
BMPR-II was absent.
Discussion
In our study BMP-2/4, -6 and -7 expression was down-
regulated in metastatic prostate cancer with established
bone metastases. Decreased expression of bone morpho-
genetic protein receptors type IA and IB, and lack of re-
ceptor type II were found in metastatic prostate cancer,
too. Metastatic cancer cells from bone lesions caused by
prostate cancer strongly expressed BMP-2/4, 6 and -7.
We have confirmed previous results that BMP-2/4, -6
and -7 and receptors BMPR-IA, -IB and -II were ex-
pressed by epithelial cells of human normal prostate
tissue19,24,33,34. We found the highest expression for
BMP-2/4 and BMP-7. Harris et al examined for BMP-2,
BMP-3, BMP-4 and BMP-6 mRNA expression in human
normal prostate and prostate cancer cell lines19. They
found that normal human prostate predominantly ex-
pressed BMP-4.
Over membrane receptor complex BMPs initiate cell
signal transduction. Since BMPRs are expressed in nor-
mal prostate, BMPs could be important factors in main-
taining of normal prostate tissue physiology and cell
growth control by acting as autocrine or paracrine
growth regulatory factors19.
In our study BMP-2/4 and -7 expression appeared to
be downregulated whereas BMP-6 expression increased
in localized prostate cancers compared with normal pros-
tate. On the other hand, we found decreased expression
of all examined BMPs in metastatic prostate cancers.
Evaluating BMPs expression through the number of
samples that showed positive immunohistochemical
staining we found that all samples of normal prostate
and with localized prostate cancer conferred a positive
reaction. The number of metastatic prostate cancer sam-
ples with BMP-6 and -7 positive immunohistochemical
reactions was significantly reduced. Our study revealed
that in metastatic prostate cancers with established bone
metastases and consequently higher Gleason score, the
expression of BMP-6 and -7 was strongly downregulated.
This finding suggests that BMPs may have an inhibitory
effect on prostate cancer tumorogenesis.
Several studies have examined the expression of
BMP-2, -4, -6 and -7 in human normal and malignant
prostate tissues. In PCR-based analysis, Bentley et al
found that several BMPs were expressed in both benign
and malignant human prostate tissue3. BMP-6 expres-
sion was detected in the prostate tissue of over 50% of pa-
tients with clinically defined metastatic prostate cancer,
but was not detected in nonmetastatic or benign prostate
samples. These results were consistent with a later study
by Hamdy et al., who reported that BMP-6 mRNA ex-
pression was detected exclusively in malignant epithelial
cells in 20 out of 21 patients with metastases, in 2 out of
11 patients with localized prostate cancer, and undetect-
able in 8 benign samples21. In the study of Harris et al,
they examined BMP-2, -3, -4 and -6 mRNA expression in
normal rat prostate and rat PAIII prostate adenocarci-
noma19. Their experiments revealed that normal rat pro-
state produces BMP-2, -3, -4 and -6 mRNA. BMP-2 and -6
mRNA expression in normal prostate tissue was consid-
erably elevated compared with PAIII cells and prostate
tumor. This same trend they reported for BMP-2 and
BMP-6 expression in normal human prostate compared
with PC-3 and LNCaP cells. In another study focused on
BMP-6 mRNA and protein expression, Barnes et al. ob-
served that BMP-6 was produced by normal and neoplas-
tic human prostate21. Furthermore, they found no signif-
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TABLE 3
EXPRESSION OF BONE MORPHOGENETIC PROTEIN RECEPTORS (BMPRs) IN NORMAL PROSTATE (NP) AND PROSTATE CANCER (PC)
(MEAN±SD)
BMPRs
Normal prostate Localized PC Metastatic PC
% positive cells no. of cases % positive cells no. of cases % positive cells no. of cases
BMPR-IA 80.52±18.3 10/10 67.25±30.71 21/21 42.73±13.09* 5/21 (24%)*
BMPR-IB 62.28±12.4 10/10 58.43±22.67 21/21 55.47±32.9 3 9/21 (43%)*
BMPR-II 41.80±11.3 10/10 45.96±32.22 21/21 negative none
* p<0.05, metastatic PC vs. localized PC
TABLE 4
EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs)
IN PROSTATE CANCER SKELETAL METASTASES TISSUE
BMPs
Skeletal metastases




icant increase in BMP-6 protein expression with tumor
grade or metastatic potential in the rat prostate adeno-
carcinoma model. Horvath et al examined BMP-2 expres-
sion in normal prostate and localized prostate cancer;
they demonstrated decreased BMP-2 expression in local-
ized prostate cancer in correlation with benign prostate
hyperplasia or hyperplasia adjacent to prostate cancer23.
Expression of BMP-7 in normal and neoplastic human
prostate was examined by Masuda et al24. They found
that the level of BMP-7 expression was highest in the
normal prostate glandular tissue in comparison to the
prostate cancer. In newly diagnosed prostate cancer tis-
sues they found lower BMP-7 expression and they con-
cluded that the expression of BMP-7 tended to be lower
during the development and progression of prostate can-
cer.
In accordance with previous results we have found de-
creased expression of BMP-2 and -7 in organ-localized
prostate cancers compared to the normal prostate tissue.
For the first time we showed the differences in the ex-
pression of BMP-7 between localized and metastatic
prostate cancers. In prostate cancers with confirmed
skeletal metastases and higher Gleason score the expres-
sion of BMP-7 significantly decreased and in 2/3 of tissue
samples was completely lost. Since systemic administra-
tion of BMP-7 inhibited prostate cancer growth in the
bone marrow we assumed that decreased BMP-7 expres-
sion is related to progression to a more aggressive form of
prostate cancer26. Horvat et al have also suggested that
decreased BMP-2 expression was related to progression
of prostate cancer since inhibitory effect was absent21.
Ide et al demonstrated that recombinant BMP-2 treat-
ment in the presence of androgen inhibits cellular prolif-
eration of androgen-responsive LNCaP cells34. Another
report demonstrated that recombinant BMP-2 had anti-
-proliferative effects in vitro on multiple tumors includ-
ing breast and lung cancers36. Feeley et al showed that
BMP-2 in dose dependent fashion effected small decrease
in cell proliferation while there was no effect on cell pro-
liferation with BMP-4 and BMP-7 at any concentration38.
BMP-7 was found positive in metastatic breast cancer4.
The results of BMP-6 expression were more controver-
sial. Several reports revealed elevated BMP-6 expression
in metastatic prostate cancers19–21, while Barnes et al has
not found increased expression of BMP-6 in higher grade
tumors22. Contrary, we found significantly decreased ex-
pression of BMP-6 in metastatic prostate cancers. BMP-6
inhibited cell proliferation although the antiproliferative
response of prostate cancer cells to BMP-6 seems con-
trary to the established correlation between aggressive
cancer and elevated BMP-6 expression39.
BMPR-IA, BMPR-IB and BMPR-II were expressed by
epithelial and in some cases by stromal cells in all sam-
ples of normal human prostate what is in correlation
with previous results30,31,34. There were no significant
differences in BMPRs expression between normal and lo-
calized prostate cancers. However, in metastatic prostate
cancers we found lower expression of all three BMPRs
compared with normal or localized prostate cancers.
BMPR-IA expression was significantly decreased in met-
astatic prostate cancers. Furthermore, BMPR-II expres-
sion was completely lost because less than 10% of posi-
tive cells were found in only 3 out of 21 metastatic
prostate cancer samples. Kim et al have previously dem-
onstrated loss of expression of the three BMP receptors
in higher grade prostate cancers, but only loss of BMPR-II
correlated with 5-year survival rate30,31. Loss of BMPR-II
expression will disrupt the function of heteromeric com-
plex of membrane receptors as BMPR-II is necessary
part for receptor activation. This was confirmed with in
vitro experiment in which BMP-6 inhibits PC3M cellular
proliferation but in the cases when prostate cancer cell
lines was transfected by dominant-negative BMPR-II,
strong inhibitory effect of BMP-6 on cell growth and pro-
liferation was absent23. They have suggested that the
neutralization of BMP signaling led to an increased
tumorogenic potential of the PC3M prostate cancer cell
line31. Ide et al have reported that BMPR-IB is androgen
dependent and they have found significantly lower
amount of BMPR-IB mRNA in all the prostate cancer tis-
sues after androgen withdrawal33. In our cases the tissue
samples of prostate cancers were collected from the pa-
tients with newly diagnosed prostate cancer and still
with normal androgen function. That can be an explana-
tion of rather similar expression of BMPR-IB that we
found between normal prostate tissue and prostate can-
cers.
We examined tissue samples of skeletal metastases
caused by prostate cancer. BMP-2/4. -6 and -7 were ex-
pressed by metastatic cancer cells. Previous results have
shown that osteoblastic bone lesions caused by prostate
cancer expressed BMP-6 and -725,29. Additionally, BMP-7
expression was not detected in normal bone tissue, un-
like BMP-6 expression that was identified in normal os-
teoblasts in skeletal tissue25,29. The expression of highly
osteogenic BMPs in bone microenvironment in meta-
static cells possibly leads and facilitates the formation of
osteoblastic bone lesions. The expression of BMPRs in
prostate cancer metastatic cells is probably low to pre-
vent the possible inhibitory effect of BMPs on cancer
cells growth.
In conclusion for the first time in our study we have
examined the expression of BMPs and BMPRs in the
same tissue samples of normal prostate, metastatic and
nonmetastatic prostate cancer. We have proved the sig-
nificant decrease of BMPs and BMPRs expression with
the progression of prostate cancer suggesting BMPs im-
portant inhibitory role. Since, the expression of BMPs
and BMPRs is similar in normal prostate and nonme-
tastatic prostate cancer we can conclude that BMPs have
insignificant or no influence on the onset of malignant
disease but can control the malignant disease progres-
sion especially bone metastising. Also for the first time
we showed high expression of osteogenic BMPs in osteo-
blastic prostate cancer bone metastases as a possible ex-
planation of their osteosclerotic characteristics.
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ULOGA KO[TANIH MORFOGENETSKIH PROTEINA U PATOGENEZI HUMANOG KARCINOMA
PROSTATE I RAZVOJU KO[TANIH METASTAZA: IMUNOHISTOKEMIJSKA STUDIJA
S A @ E T A K
Ko{tani morfogenetski protein (BMP) imaju sposobnost indukcije ektopi~nog stvaranja kosti1–9. Njihova ekspresija
u stanicama carcinoma prostate povezana je s tumorskom progresijom u kosti i razvojem osteoskleroti~nih metasta-
za10–15. U ovoj studiji istra`ili smo obrasce ekspresije BMP-2/4, -6 i 7 te receptora BMPR-IA, IB i II u normalnoj humanoj
prostati, organ ograni~enom karcinomu prostate i metastatskom karcinomu prostate. Ekspresiju smo istra`ili i u sa-
mim ko{tanim metastazama. U lokaliziranom karcinomu prostate uo~ili smo poja~anu ekspresiju BMP-6, a smanjenu
BMP-2/4 i 7. U metastatskom karcinomu ekspresija BMP-a je smanjena. Ekspresija BMPR-a se smanjivala s progre-
sijom karcinoma prostate, a ekspresija BMPR-II je potpuno odsutna u metastatskom karcinomu prostate. U ko{tanim
metastazama karcinoma prostate prona{li smo ekspresiju BMP-2/4, -6 i -7. Smanjena ekspresija BMP-a i gubitak eks-
presije BMPR-II mo`e upu}ivati na inhibitornu ulogu BMP-a na stanice karcinoma prostate te na njihovu va`nu ulogu
u patogenezi karcinoma prostate. Izra`ena ekspresija osteogenih BMP-a u ko{tanim metastazama karcinoma prostate
mo`e objasniti njihovu osteoskleroti~nu prirodu.
J. [panjol et al.: Bone Morphogenetic Proteins and Prostate Cancer, Coll. Antropol. 34 (2010) Suppl. 2: 119–125
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